[Skip to Content]
[Skip to Content Landing]
April 21, 1993

Transdermal Nicotine: Clarifications, Side Effects, and Funding

Author Affiliations

Group Health Cooperative of Puget Sound Seattle, Wash

JAMA. 1993;269(15):1939-1940. doi:10.1001/jama.1993.03500150047014

To the Editor.  —In their excellent Review, "Tobacco Dependence and the Nicotine Patch," Fiore et al1 raise concerns about the public health limitations of transdermal patches. They specifically recommend that the pharmaceutical industry "commit 1% or 2% of their gross sales to finance an independently directed, antismoking media campaign or other public health intervention...."Group Health Cooperative of Puget Sound in Washington State is a staff model health maintenance organization with 800 physicians and 400 000 members. We recently decided to pay for transdermal nicotine patch therapy when used in conjunction with our behavioral smoking cessation programs. As part of the bid solicitation process to determine which patch to place on our formulary, we asked patch companies if they would be willing to provide us with funding for an independent antismoking media campaign and a project to prevent tobacco use in children. Most companies responded favorably. Their responses were